Aa
A
A
Close
Avatar universal
Gilead GS9620 Prediction
I am making a prediction that this drug will be released by Gilead in 2017/2018.

Why?  Gilead loses the patent on Viread in 2017/2018.  Their cash cow will have run its course and they will be more than happy to release this drug to continue to reap the money for HBV treatment.  

There is one thing I remember Dr. Gish telling me that I won't forget.  He said "you know Gilead is working on a drug that will make it so you don't have to take Viread for ever.  It's kind of odd that they'd be working on a drug that will eliminate their Viread income".  

Not really.  If they release it when Viread loses patent, it's a win-win for them!
Cancel
7 Answers
Page 1 of 1
Avatar universal
"I am making a prediction that this drug will be released by Gilead in 2017/2018. "

Provided that GS9620 shows the expected efficacy on hbvers (and hcvers).
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Avatar universal
They've already done small cohort human trials, and the drug works and is well tolerated.  
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Avatar universal
Really?  They already have a small amount of data on hbvers (human), not just healthy volunteers?  Were they cured?  If so, that would be truly exciting.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Avatar universal

i do hope myrcludex and replicor are able to fasten this process or imiquimod itself show some effect, this is the only thing to make them move very fast

Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Avatar universal
So,
Now, we have three horses running in the course: rep9ac(replicor), mycrludex and GS9620 ..

Good ,, i hope number of horses will increase ..
at least one of them reach to the finalist soooon ..
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Avatar universal
Actually there are 4, if you include the sRNAi from Arrowhead Research.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Avatar universal
Had appt with Gish - he said there is unreleased data from clinical trials showing GS 9620 has been effective, and non-toxic in escalating doses.  He also said clinical trials are still ongoing and they've relaxed the inclusion criteria, so others may be able to join (veteranB).
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Your Answer
Avatar universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
Submit Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
233488 tn?1310696703
Blank
Marathon Running Done Over Many Yea...
05/15 by John C Hagan III, MD, FACS, FAAOBlank
233488 tn?1310696703
Blank
New Article on Multifocal IOL vs &q...
05/15 by John C Hagan III, MD, FACS, FAAOBlank
748543 tn?1463449675
Blank
TMJ/TMJ The Connection Between Teet...
01/15 by Hamidreza Nassery , DMD, FICOI, FAGD, FICCMOBlank
Top Hepatitis Answerers
Avatar universal
Blank
Italy
Avatar universal
Blank
Other
Avatar universal
Blank
Poland
Avatar universal
Blank
Australia
Avatar universal
Blank
India
Avatar universal
Blank
los angeles, CA